Literature DB >> 23395113

Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.

Marcelo Actis1, Akira Inoue, Benjamin Evison, Scott Perry, Chandanamali Punchihewa, Naoaki Fujii.   

Abstract

Proliferating cell nuclear antigen (PCNA) is an essential component for DNA replication and DNA damage response. Numerous proteins interact with PCNA through their short sequence called the PIP-box to be promoted to their respective functions. PCNA supports translesion DNA synthesis (TLS) by interacting with TLS polymerases through PIP-box interaction. Previously, we found a novel small molecule inhibitor of the PCNA/PIP-box interaction, T2AA, which inhibits DNA replication in cells. In this study, we created T2AA analogues and characterized them extensively for TLS inhibition. Compounds that inhibited biochemical PCNA/PIP-box interaction at an IC50 <5 μM inhibited cellular DNA replication at 10 μM as measured by BrdU incorporation. In cells lacking nucleotide-excision repair activity, PCNA inhibitors inhibited reactivation of a reporter plasmid that was globally damaged by cisplatin, suggesting that the inhibitors blocked the TLS that allows replication of the plasmid. PCNA inhibitors increased γH2AX induction and cell viability reduction mediated by cisplatin. Taken together, these findings suggest that inhibitors of PCNA/PIP-box interaction could chemosensitize cells to cisplatin by inhibiting TLS.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23395113     DOI: 10.1016/j.bmc.2013.01.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

Review 1.  Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities.

Authors:  Maroof K Zafar; Robert L Eoff
Journal:  Chem Res Toxicol       Date:  2017-09-28       Impact factor: 3.739

2.  Small-molecules that bind to the ubiquitin-binding motif of REV1 inhibit REV1 interaction with K164-monoubiquitinated PCNA and suppress DNA damage tolerance.

Authors:  Murugendra Vanarotti; Benjamin J Evison; Marcelo L Actis; Akira Inoue; Ezelle T McDonald; Youming Shao; Richard J Heath; Naoaki Fujii
Journal:  Bioorg Med Chem       Date:  2018-03-19       Impact factor: 3.641

Review 3.  The Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibition.

Authors:  Alessandro A Rizzo; Dmitry M Korzhnev
Journal:  Enzymes       Date:  2019-08-09

4.  A site-selective, irreversible inhibitor of the DNA replication auxiliary factor proliferating cell nuclear antigen (PCNA).

Authors:  Benjamin J Evison; Marcelo L Actis; Sean Z Wu; Youming Shao; Richard J Heath; Lei Yang; Naoaki Fujii
Journal:  Bioorg Med Chem       Date:  2014-10-08       Impact factor: 3.641

5.  Recognition of a Key Anchor Residue by a Conserved Hydrophobic Pocket Ensures Subunit Interface Integrity in DNA Clamps.

Authors:  Senthil K Perumal; Xiaojun Xu; Chunli Yan; Ivaylo Ivanov; Stephen J Benkovic
Journal:  J Mol Biol       Date:  2019-04-30       Impact factor: 5.469

6.  A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.

Authors:  Akira Inoue; Sotaro Kikuchi; Asami Hishiki; Youming Shao; Richard Heath; Benjamin J Evison; Marcelo Actis; Christine E Canman; Hiroshi Hashimoto; Naoaki Fujii
Journal:  J Biol Chem       Date:  2014-01-28       Impact factor: 5.157

7.  Target validation and structure-activity analysis of a series of novel PCNA inhibitors.

Authors:  Kelsey L Dillehay; William L Seibel; Daoli Zhao; Shan Lu; Zhongyun Dong
Journal:  Pharmacol Res Perspect       Date:  2015-03

8.  Inhibition of DNA replication by an anti-PCNA aptamer/PCNA complex.

Authors:  Ewa Kowalska; Filip Bartnicki; Ryo Fujisawa; Piotr Bonarek; Pawel Hermanowicz; Toshiki Tsurimoto; Klaudia Muszynska; Wojciech Strzalka
Journal:  Nucleic Acids Res       Date:  2018-01-09       Impact factor: 16.971

9.  Flexibility of PCNA-protein interface accommodates differential binding partners.

Authors:  Anthony M Pedley; Markus A Lill; V Jo Davisson
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

Review 10.  Translesion synthesis inhibitors as a new class of cancer chemotherapeutics.

Authors:  Seema M Patel; Radha Charan Dash; M Kyle Hadden
Journal:  Expert Opin Investig Drugs       Date:  2020-12-03       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.